Page 19 - 2022-23-中国全科医学

·2832· http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn

DOI：10.1002/14651858.CD013165.pub2. hyperglycaemia［J］. Diabetes Obes Metab，2013，15（12）：
［43］中国医师协会心血管内科医师分会心力衰竭学组，中国心力衰 1154-1160. DOI：10.1111/dom.12185.
竭患者高钾血症管理专家共识工作组 . 中国心力衰竭患者高钾 ［56］顾金金，韩丽娜，刘强 . ACEI 与 ARB 联合治疗临床糖尿病
血症管理专家共识［J］. 中华医学杂志，2021，101（42）： 肾病的疗效与安全性的 Meta 分析［J］. 中南大学学报：医
3451-3458. 学 版，2013，38（6）：623-630. DOI：10.3969/j.issn.1672-
［44］SHRESTHA D B，BUDHATHOKI P，SEDHAI Y R，et al. 7347.2013.06.012.
Patiromer and sodium zirconium cyclosilicate in treatment of ［57］MAJIMA T，KOMATSU Y，DOI K，et al. Safety and efficacy
hyperkalemia：a systematic review and meta-analysis［J］. of low-dose pioglitazone （7.5 mg/day） vs. standard-dose
Curr Ther Res Clin Exp，2021，95：100635. DOI：10.1016/j. pioglitazone （15 mg/day） in Japanese women with type 2 diabetes
curtheres.2021.100635. mellitus［J］. Endocr J，2006，53（3）：325-330. DOI：
［45］PERKOVIC V，JARDINE M J，NEAL B，et al. Canagliflozin 10.1507/endocrj.k05-067.
and renal outcomes in type 2 diabetes and nephropathy［J］. ［58］ZIAEE A，ABBAS VAEZI A，OVEISI S，et al. Effects of additive
N Engl J Med，2019，380（24）：2295-2306. DOI： therapy with spironolactone on albuminuria in diabetes mellitus：a
10.1056/NEJMoa1811744. pilot randomized clinical trial［J］. Caspian J Intern Med，2013，
［46］Aspirin Effects on Mortality and Morbidity in Patients with Diabetes 4（2）：648-653.
Mellitus. Early Treatment Diabetic Retinopathy Study report 14. ［59］MEHDI U F，ADAMS-HUET B，RASKIN P，et al. Addition
ETDRS Investigators［J］. JAMA，1992，268（10）：1292- of angiotensin receptor blockade or mineralocorticoid antagonism
1300. DOI：10.1001/jama.1992.03490100090033. to maximal angiotensin-converting enzyme inhibition in diabetic
［47］JARDINE M J，NINOMIYA T，PERKOVIC V，et al. Aspirin is nephropathy［J］. J Am Soc Nephrol，2009，20（12）：2641-
beneficial in hypertensive patients with chronic kidney disease： 2650. DOI：10.1681/asn.2009070737.
a post-hoc subgroup analysis of a randomized controlled trial［J］. ［60］AGARWAL R，JOSEPH A，ANKER S D，et al. Hyperkalemia
J Am Coll Cardiol，2010，56（12）：956-965. DOI：10.1016/j. risk with finerenone：results from the FIDELIO-DKD trial［J］.
jacc.2010.02.068. J Am Soc Nephrol，2022，33（1）：225-237. DOI：
［48］MCNEIL J J，WOLFE R，WOODS R L，et al. Effect of aspirin 10.1681/ASN.2021070942.
on cardiovascular events and bleeding in the healthy elderly［J］. ［61］FILIPPATOS G，ANKER S D，AGARWAL R，et al. Finerenone
N Engl J Med，2018，379（16）：1509-1518. DOI： reduces risk of incident heart failure in patients with chronic kidney
10.1056/NEJMoa1805819. disease and type 2 diabetes：analyses from the FIGARO-DKD
［49］MOSENZON O，WIVIOTT S D，CAHN A，et al. Effects of trial［J］. Circulation，2022，145（6）：437-447. DOI：
dapagliflozin on development and progression of kidney disease in 10.1161/CIRCULATIONAHA.121.057983.
patients with type 2 diabetes：an analysis from the DECLARE-TIMI ［62］OXLUND C S，HENRIKSEN J E，TARNOW L，et al. Low dose
58 randomised trial［J］. Lancet Diabetes Endocrinol，2019，7（8）： spironolactone reduces blood pressure in patients with resistant
606-617. DOI：10.1016/S2213-8587（19）30180-9. hypertension and type 2 diabetes mellitus：a double blind
［50］WANNER C，INZUCCHI S E，LACHIN J M，et al. Empagliflozin randomized clinical trial［J］. J Hypertens，2013，31（10）：
and progression of kidney disease in type 2 diabetes［J］. 2094-2102. DOI：10.1097/HJH.0b013e3283638b1a.
N E ng l J M e d，2016，375（4）：323-334. DOI： ［63］ITO S，SHIKATA K，NANGAKU M，et al. Efficacy and safety
10.1056/NEJMoa1515920. of esaxerenone （CS-3150） for the treatment of type 2 diabetes
［51］ZINMAN B，WANNER C，LACHIN J M，et al. Empagliflozin， with microalbuminuria：a randomized，double-blind，placebo-
cardiovascular outcomes，and mortality in type 2 diabetes［J］. controlled，phase II trial［J］. Clin J Am Soc Nephrol，2019，
N Engl J Med，2015，373（22）：2117-2128. DOI： 14（8）：1161-1172. DOI：10.2215/CJN.14751218.
10.1056/NEJMoa1504720. ［64］VAN DEN MEIRACKER A H，BAGGEN R G，PAULI S，
［52］WANNER C，INZUCCHI S E，ZINMAN B，et al. Consistent et al. Spironolactone in type 2 diabetic nephropathy：effects
effects of empagliflozin on cardiovascular and kidney outcomes on proteinuria，blood pressure and renal function［J］.
irrespective of diabetic kidney disease categories：insights from the J Hypertens，2006，24（11）：2285-2292. DOI：10.1097/01.
EMPA-REG OUTCOME trial［J］. Diabetes Obes Metab，2020， hjh.0000249708.44016.5c.
22（12）：2335-2347. DOI：10.1111/dom.14158. ［65］KATO S，MARUYAMA S，MAKINO H，et al. Anti-
［53］FIORETTO P，DEL PRATO S，BUSE J B，et al. Efficacy and albuminuric effects of spironolactone in patients with type 2 diabetic
safety of dapagliflozin in patients with type 2 diabetes and moderate nephropathy：a multicenter，randomized clinical trial［J］. Clin
renal impairment （chronic kidney disease stage 3A）：the Exp Nephrol，2015，19（6）：1098-1106. DOI：10.1007/
DERIVE Study［J］. Diabetes Obes Metab，2018，20（11）： s10157-015-1106-2.
2532-2540. DOI：10.1111/dom.13413. ［66］EL MOKADEM M，ABD EL HADY Y，AZIZ A. A prospective
［54］BHATT D L，SZAREK M，PITT B，et al. Sotagliflozin in patients single-blind randomized trial of ramipril，eplerenone and their
with diabetes and chronic kidney disease［J］. N Engl J Med， combination in type 2 diabetic nephropathy［J］. Cardiorenal
2021，384（2）：129-139. DOI：10.1056/NEJMoa2030186. Med，2020，10（6）：392-401. DOI：10.1159/000508670.
［55］ROSENSTOCK J，SEMAN L J，JELASKA A，et al. Efficacy and ［67］EPSTEIN M，WILLIAMS G H，WEINBERGER M，et al.
safety of empagliflozin，a sodium glucose cotransporter 2 （SGLT2） Selective aldosterone blockade with eplerenone reduces albuminuria
inhibitor，as add-on to metformin in type 2 diabetes with mild in patients with type 2 diabetes［J］. Clin J Am Soc Nephrol，